Christopher Yasenchak, MD, on the most impressive data in the treatment of Hodgkin’s lymphoma

Optimal therapy sequencing for Hodgkin lymphomaПодробнее

Dr. Yasenchak on Brentuximab Vedotin Added to R-CHOP in DLBCLПодробнее

Constantine Tam, MBBS, MD, regarding the data that lead to the recent FDA approval of zanubrutinibПодробнее

Hodgkin's Disease or Non-Hodgkin's Lymphoma Diagnosis and TreatmentПодробнее

Expert Discusses Treatment Options for HCC According to Disease StageПодробнее

Targeted desialylation as a therapeutic strategy in MMПодробнее

Data on new therapeutic strategies in Hodgkin lymphomaПодробнее

Christopher Yasenchak, MD, tells us about the patient profile most suited for zanubrutinib in MCLПодробнее

The safety and efficacy of the Syk inhibitor sovleplenib in heavily pre-treated Hodgkin lymphomaПодробнее

EBMT 2018: Updates on advanced Hodgkin lymphoma treatmentПодробнее

Constantine Tam, MBBS, MD, regarding the patient profile in MCL most suitable for zanubrutinibПодробнее

Michael Atkins, MD, regarding single agent TKIs in the 1st line settingПодробнее

Meet Oncologist Dr. Abraham ChachouaПодробнее

Novel targets and agents for lymphomaПодробнее

Michael Atkins, MD, on appropriate patient types to receive a TKI in the treatment of 1st line RCCПодробнее

Michael B. Atkins, MD, considers preferred agents in the treatment of RCC in the 2nd lineПодробнее

Patient selection in the treatment of NHLПодробнее

Michael B. Atkins, MD, on the role of IMDC classification in treatment decision-makingПодробнее

Christopher Bichakjian, MD - Video ProfileПодробнее